DisclosureWe earn commission on partner links; ranking is set by our published methodology — not advertisers.
Lilly's triple agonist posted numbers no obesity drug has matched: up to ~28–30% average weight loss, around 85 pounds in the highest-BMI group. It is also not FDA-approved, will not be until 2027 at the earliest, and cannot be bought safely today. Here is the real data and the real timeline — no hype.
Retatrutide is a “triple-G” agonist. Where Wegovy (semaglutide) activates one receptor (GLP-1) and Zepbound (tirzepatide) activates two (GIP + GLP-1), retatrutide adds a third: the glucagon receptor. GLP-1 and GIP suppress appetite; glucagon activation raises energy expenditure and directly targets liver fat. That extra mechanism is the leading explanation for why its trial weight loss exceeds every prior drug. Like the others, it is a once-weekly injection.
These are the published Phase 3 figures — not projections:
| Trial | Result | Detail |
|---|---|---|
| TRIUMPH-1 | ~28.3% at 80 weeks | 45% of 12 mg patients lost ≥30% of body weight |
| TRIUMPH-1 extension | up to ~30.3% at 104 weeks | ~85 lb average in the BMI ≥35 group |
| TRIUMPH-4 | ~28.7% at 68 weeks | reported December 2025 |
| TRANSCEND-T2D-1 | 16.8% loss + −2.0% HbA1c | type 2 diabetes; Lancet, June 2026 |
For a like-for-like sense of scale, see how the approved drugs compare in Wegovy vs Zepbound— retatrutide’s ~28–30% sits meaningfully above Zepbound’s ~21%, which is itself the current approved leader.
Impressive data is not availability. Lilly is expected to submit the FDA application around Q4 2026. A standard FDA review then runs roughly a year, so the earliest realistic launch is 2027, and only if the filing and review go smoothly. Several more Phase 3 TRIUMPH trials are still reading out through 2026. If you see a date earlier than that, or an “available now,” it is wrong.
Because the drug is not approved, there is no legal source— not a pharmacy, not a compounding pharmacy (compounding legally requires an FDA-approved reference product, and retatrutide has none). Vials of “research retatrutide” on the grey market are unregulated chemicals of unknown identity, dose, and purity, dosed in units that are a documented overdose route. There is no version of buying retatrutide today that is both legal and safe. The same warning covers “tirzepatide tablets” and other not-yet-real products.
For most people, no. Retatrutide is a year or two out, its real-world safety record does not exist yet, and the weight you could lose on an approved drug during that wait is real. Zepbound already delivers ~21% and is available now; the new oral options (Foundayo, oral Wegovy) add needle-free choices. Treat obesity with an approved option now, and revisit retatrutide if and when it launches — use our which-GLP-1 quiz to start.